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background: The degree of device oversizing associated with optimal clinical outcomes differs between current transcatheter heart valve (THV) 
devices. With limited THV sizes some annuli considered borderline for one device may be within an optimal range for another device. We sought to 
determine whether transcatheter aortic valve replacement (TAVR) within annuli considered borderline for either a SAPIEN XT or CoreValve device may 
show improved clinical outcomes utilizing the other device.
Methods: We analyzed a multicenter database of consecutive TAVR procedures using SAPIEN XT and CoreValve. Optimal oversizing was defined for 
SAPIEN XT (5-20% by area or 2.5-9.5% by perimeter) and for CoreValve (20-35% by area or 9.5-16.2% by perimeter). Implantations within annuli 
outside of this optimal range were thus in the “borderline zone” for that device and were compared with procedures performed in similar sized 
annuli using the other THV device.
results: A total of 419 patients undergoing TAVR within annuli in the “borderline zone” for a specific THV device were included. Irrespective of the 
device chosen, cardiac tamponade and annular rupture were more common when a THV device was implanted within borderline zone annuli, in 
comparison with controls utilizing the other THV device (Table).
conclusions: An individualized approach utilizing a specific THV (CoreValve or SAPIEN XT) that enables an optimal degree of device oversizing may 
improve clinical outcomes after TAVR. 
